



POSTERS OVERVIEW

- 1 **KCNQ/KV7 CHANNELS LOCALIZE TO DENDRITIC SPINES VIA ANKYRING-190 AND SUPPRESS NMDA RECEPTOR ACTIVITY** – *Hongyu Zhao (United States of America)*
- 2 **FROM CELL CULTURE TO CRYO EM: MEMBRANE PROTEIN PURIFICATION OF KV7.1 CHANNEL FROM MAMMALIAN CELLS** – *Minay Mertens (Germany)*
- 3 **A HIGH-THROUGHPUT FUNCTIONAL SCAN OF KCNQ1 S4 VARIANTS** – *Eduardo Guadarrama (United States of America)*
- 4 **CONTRIBUTION OF KV7 CHANNELS TO VASCULAR TONE REGULATION IN HUMAN AND RAT RENAL RESISTANCE VESSELS** – *Max Jarchow (Germany)*
- 5 **MELATONIN AND MELATONIN-DERIVED, H₂S-CONTAINING COMPOUNDS ACT AS NEW KV7.4 ACTIVATORS** – *Dania Iola (Italy)*
- 6 **KV7.2 CHANNELOPATHY BEYOND THE BRAIN: GAIN-OF-FUNCTION VARIANTS LINKED TO PALATAL MALFORMATIONS** – *Kim Marie Thalwitzer (Germany)*
- 7 **NOT JUST BRAINY BUT ALSO BRAWNY: THE ROLE OF KV7 CHANNELS BEYOND THE BRAIN** – *Noemi Di Muraglia (Italy)*
- 8 **KV7/KCNQ CHANNEL BLOCKADE ATTENUATES HIPPOCAMPAL BUT NOT RETINAL DEGENERATION IN CLCN3-/- MICE** – *Alberto Rafael Diaz Castillo (Germany)*
- 9 **SIX NOVEL VARIANTS IN KV7.2 POTASSIUM CHANNELS CAUSE DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY BY GAIN-OF-FUNCTION EFFECTS** – *Antonio Priore (Italy)*
- 10 **A NOVEL ROLE FOR KININOGEN IN THE REGULATION OF KV7 CHANNEL ACTIVITY AND NEURONAL EXCITABILITY IN MULTIPLE SCLEROSIS** – *Nicole Rychlik (Germany)*
- 11 **TMPRSS6 CLEAVES KCNE1 AND CAUSES ARRHYTHMIAS IN IRON OVERLOAD DISEASE** – *Ricarda Zimmermann (Germany)*
- 12 **KCNQ2-DEE: ARE NAV1.1 AND NAV1.6 CHANNELS INVOLVED IN THE SUDEP PHENOTYPE OBSERVED IN THE KCNQ2T274M/+ MOUSE MODEL?** – *Manon Saurey (France)*
- 13 **IKS SINGLE CHANNELS: A SURVEY.** – *Jodene Eldstrom (Canada)*
- 14 **THE INTERMEDIATE STATE STRUCTURE OF KCNQ1 ILLUMINATES VOLTAGE SENSOR DYNAMICS** – *Efthimios Kyriakis (Canada)*
- 15 **MECHANISM OF KCNQ1 GATING REGULATED BY PIP2 AND CALMODULIN** – *Jingyi Shi (United States of America)*
- 16 **17B-OESTRADIOL INHIBITS KV7.4 CHANNELS VIA GPER1-GQ-PLC-PKC SIGNALLING** – *Iain A Greenwood (United Kingdom)*
- 17 **DRUG:LIPID INTERACTIONS REVEAL AN ENORMOUS DYNAMIC RANGE OF KCNQ POTASSIUM CHANNEL REGULATION** – *Harley Kurata (Canada)*
- 18 **KCNE0, AN EARLY DIVERGING KCNE SUBUNIT, CONFERS CONSTITUTIVE ACTIVITY TO KCNQ1 IN LAMPREY** – *Koichi Nakajo (Japan)*
- 19 **BINDING SITE AND PUTATIVE MECHANISTIC INSIGHTS INTO THE INHIBITORY EFFECT OF ESTRADIOL (17B-E2) ON THE KV7.1/KCNE1 CHANNEL** – *Veronika Linhart (Sweden)*
- 20 **PHARMACOLOGICAL IMPLICATIONS OF β -ADRENERGIC PHOSPHORYLATION OF KV7.1/KCNE1** – *Mika Jönsson (Sweden)*
- 21 **AN INTEGRATED ASSAY PLATFORM FOR MECHANISTIC AND TRANSLATIONAL PROFILING OF KV7.2/7.3 ACTIVATORS** – *Catherine M. Hodgson (United Kingdom)*
- 22 **MOLECULAR BASIS FOR SELECTIVE ACTIVATION OF KV7.3 BY THE ROSEMARY METABOLITE CARNOSIC ACID** – *Geoffrey Abbott (United States of America)*
- 23 **VOLTAGE CLAMP FLUOROMETRY IN KV7.4 TO DETERMINE PHARMACOLOGICAL MECHANISMS** – *Ricardo Pan-Lizcano (Sweden)*
- 24 **EFFECT OF ‘SQUEEZE-TO-INHIBIT’ AGENT EBIO3 ON SMOOTH MUSCLE RELAXATIONS** – *Ugo Ejiegbu (United Kingdom)*
- 25 **BEYOND RETIGABINE: ELECTROPHYSIOLOGICAL CHARACTERIZATION OF AZETUKALNER ACROSS KV7/KCNE COMPLEXES** – *Johann W. Schröder (Germany)*
- 26 **THE PARACETAMOL METABOLITE NAPQI PREVENTS GPCR-MEDIATED INHIBITION OF KV7 CHANNELS** – *Isabella Salzer (Austria)*
- 27 **CONSERVED BINDING SITE, DIVERGENT MODULATION: RETHINKING MAXIPOST SELECTIVITY ACROSS KV7 CHANNELS** – *Andrea Pasquadibisceglie (Italy)*
- 28 **BIOPHYSICAL AND PHARMACOLOGICAL CHARACTERIZATION OF KV7.4 CHANNELS USING AUTOMATED PATCH CLAMP** – *Duncan Jarman (Denmark)*
- 29 **GENOTYPE-PHENOTYPE CORRELATIONS IN KV7.2-RELATED EPILEPSIES CAUSED BY DISTINCT MUTATIONS ON THE SAME RESIDUE** – *Ilaria Mosca (Italy)*
- 30 **KV7.4 ACTIVATION PROTECTS DOPAMINERGIC NEURONS AGAINST α -SYNUCLEIN/ROTENONE-INDUCED TOXICITY: A NOVEL PHARMACOLOGICAL TARGET IN PARKINSON’S DISEASE?** – *Silvia Piccirillo (Italy)*
- 31 **QRL-101-05: A DOUBLE BLIND RANDOMIZED THREE-WAY CROSSOVER PHASE 1 STUDY TO EVALUATE CORTICAL AND MOTOR NERVE EXCITABILITY IN HEALTHY VOLUNTEERS FOLLOWING ADMINISTRATION OF A KV7.2/7.3 MODULATOR; QRL-101** – *Taylor Gray (United States of America)*
- 32 **ENDOCANNABINOID DERIVATIVES FOR SELECTIVE ACTIVATION OF KV7.1/KCNE1 IN THE CONTEXT OF LONG QT SYNDROME** – *Irene Hiniesto-Iñigo (Sweden)*
- 33 **FROM GENE TO FUNCTION: GENERATING STABLE KCNQ ISOFORM CELL LINES FOR SELECTIVE DRUG PROFILING** – *Nadine Mengers (Germany)*
- 34 **PREVENTING KV7 DOWNREGULATION BY TARGETING REST UPREGULATION IN CHRONIC PAIN** – *Nikita Gamper (United Kingdom)*
- 35 **THE NOVEL KV7 ACTIVATOR C60 REDUCES PAIN IN OXALIPLATIN-INDUCED PERIPHERAL NEUROPATHY** – *Flavia De Martino (Italy)*
- 36 **PHYSICOCHEMICAL OPTIMIZATION OF NICOTINAMIDE-BASED KV7.2/3 CHANNEL MODULATORS TO OVERCOME THE POTENCY-SOLUBILITY TRADE-OFF** – *Pascal Rosendahl (Germany)*
- 37 **FROM PATIENT NEED TO SHARED STRATEGY: BUILDING A PARTICIPATORY REGISTRY NETWORK FOR KCNQ2-RELATED EPILEPSY** – *Pasqualina Cordella (Italy)*
- 38 **HIGH-THROUGHPUT ELECTROPHYSIOLOGICAL CHARACTERIZATION OF KV7.2/KV7.3 CHANNELS USING AUTOMATED PATCH CLAMP** – *Will Seibertz (Germany)*